| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 140,400 | $1 | $561.6K |
| J0897 | Injection, denosumab, 1 mg | 24,420 | $20 | $415.1K |
| J3262 | Injection, tocilizumab, 1 mg | 91,720 | $1 | $366.9K |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 43,260 | $10 | $346.1K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,970 | $110 | $212.3K |
| 96401 | The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient. | 1,460 | $60 | $93.2K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 4,010 | $20 | $72.2K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 290 | $120 | $34.5K |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg | 1,120 | $10 | $14.6K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 100 | $130 | $13.4K |